NGS rEvolution – Minimal Residual Disease Detection <=> Maximal Relapse Prevention

Development of techniques in molecular biology over the last couple of years has not influenced only rEvolution (revolution + evolution) in HLA typing but also in other segments of onco-diagnostics and transplant medicine. Evaluation and implementation of Next Generation Sequencing (NGS) technology in Minimal Residual Disease (MRD) detection and...

 

Read more

Welcome to the Team, Elmar!

We are proud to announce and welcome Elmar Schilling, who has recently joined our company as the Chief Technology Officer of Omixon. Elmar was born and raised in   Bavaria, the southern part of   Germany. He graduated in   Molecular Biology and   completed his PhD studies   in the field of Epigenetics at   Regensburg...

 

Read more